Xilio Therapeutics Statistics Share Statistics Xilio Therapeutics has 51.83M
shares outstanding. The number of shares has increased by 17.81%
in one year.
Shares Outstanding 51.83M Shares Change (YoY) 17.81% Shares Change (QoQ) 0.02% Owned by Institutions (%) 26.2% Shares Floating 18.37M Failed to Deliver (FTD) Shares 3,698 FTD / Avg. Volume 0.64%
Short Selling Information The latest short interest is 4.31M, so 8.31% of the outstanding
shares have been sold short.
Short Interest 4.31M Short % of Shares Out 8.31% Short % of Float 12.16% Short Ratio (days to cover) 9.52
Valuation Ratios The PE ratio is -0.88 and the forward
PE ratio is -2.32.
Xilio Therapeutics's PEG ratio is
0.01.
PE Ratio -0.88 Forward PE -2.32 PS Ratio 8.06 Forward PS 0.7 PB Ratio 2.9 P/FCF Ratio -2.78 PEG Ratio 0.01
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Xilio Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 2.21,
with a Debt / Equity ratio of 0.46.
Current Ratio 2.21 Quick Ratio 2.21 Debt / Equity 0.46 Debt / EBITDA -0.14 Debt / FCF -0.44 Interest Coverage -605.82
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $99.13K Profits Per Employee $-910.02K Employee Count 64 Asset Turnover 0.09 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by -9.76% in the
last 52 weeks. The beta is -0.11, so Xilio Therapeutics's
price volatility has been lower than the market average.
Beta -0.11 52-Week Price Change -9.76% 50-Day Moving Average 0.7 200-Day Moving Average 0.82 Relative Strength Index (RSI) 56.73 Average Volume (20 Days) 574,809
Income Statement In the last 12 months, Xilio Therapeutics had revenue of 6.34M
and earned -58.24M
in profits. Earnings per share was -1.09.
Revenue 6.34M Gross Profit 6.34M Operating Income -60.58M Net Income -58.24M EBITDA -58M EBIT -59.65M Earnings Per Share (EPS) -1.09
Full Income Statement Balance Sheet The company has 55.29M in cash and 8.14M in
debt, giving a net cash position of 47.15M.
Cash & Cash Equivalents 55.29M Total Debt 8.14M Net Cash 47.15M Retained Earnings -383.75M Total Assets 133.81M Working Capital 70.46M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -18.38M
and capital expenditures -36K, giving a free cash flow of -18.41M.
Operating Cash Flow -18.38M Capital Expenditures -36K Free Cash Flow -18.41M FCF Per Share -0.34
Full Cash Flow Statement Margins Gross margin is 100%, with operating and profit margins of -954.95% and -918.05%.
Gross Margin 100% Operating Margin -954.95% Pretax Margin -918.05% Profit Margin -918.05% EBITDA Margin -914.27% EBIT Margin -954.95% FCF Margin -290.26%
